scholarly journals Eribulin and Confusion: A Previously Unknown Drug Side-Effect

2020 ◽  
Author(s):  
Abu Baker Sheikh ◽  
Abhilash Perisetti ◽  
Nismat Javed ◽  
Rahul Shekhar
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Antineoplastic Agent ◽  
Advanced Breast ◽  
Central Nervous System Drug ◽  
Drug Induced ◽  
Steroid Administration ◽  
Treatment Regimens ◽  
Aged Woman ◽  
Middle Aged Woman

Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. A wide variety of side effects with unclear mechanisms have been noted, but encephalopathy has not been widely reported. Here we describe the case of a middle-aged woman treated with eribulin for advanced breast cancer who subsequently developed central nervous system drug-induced toxicity but improved promptly with steroid administration.

scholarly journals Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane

2019 ◽  
Vol 14 (4) ◽  
pp. 441-451 ◽  
Author(s):  
Annelieke E. C. A. B. Willemsen ◽  
Jolien Tol ◽  
Nielka P. van Erp ◽  
Marianne A. Jonker ◽  
Maaike de Boer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Interstitial Lung Disease ◽  
Prospective Study ◽  
Advanced Breast Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Drug Induced

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.

1988 ◽  
Vol 6 (4) ◽  
pp. 679-688 ◽  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Response Rate ◽  
Performance Status ◽  
Menopausal Status ◽  
Complete Response ◽  
Advanced Breast ◽  
Phase Iii ◽  
Recurrence Time ◽  
Treatment Regimens

Two hundred sixty-three patients with advanced breast cancer were randomized to two treatment regimens consisting of fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin (Farmorubicin, Farmitalia Carlo Erba SpA, Italy), 50 mg/m2 (FEC); or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), 50 mg/m2 (FAC), administered intravenously (IV) every 3 weeks. Two hundred thirty patients (FAC, 113; FEC, 117) were evaluable for response, and 244 patients for toxicity (FAC, 120; FEC, 124). The two groups were comparable with respect to age, menopausal status, disease-free interval to first recurrence, time from initial diagnosis to protocol activation, indicator lesions, performance status, and prior adjuvant therapy. Of 117 evaluable patients treated with FEC, 59 (50.4%) had a partial response (PR) or complete response (CR), 40 showed no change (NC), and 18 had progressive disease. Of 113 evaluable patients treated with FAC, 54 (52%) showed a remission, 30 NC, and 18 progression. There was no statistical difference between the two regimens in overall response rate, response rate according to tumor site, time to response, or duration of response. Median survival was 15 months for FEC and 18.2 months for FAC (not significant). In the 120 patients evaluable for toxicity treated with FAC, three episodes of congestive heart failure (CHF) were observed after 225, 350, and 550 mg/m2 of doxorubicin, respectively. Of the 124 evaluable patients treated with FEC, 25 received greater than 600 mg/m2 of epirubicin and no CHF was recorded. FEC induced significantly less neutropenia (P = .01), less nausea and vomiting (P less than .01), and less complete alopecia (P less than 10(-3) than did FAC. The results of this study demonstrate that FEC is as effective a regimen as FAC for the therapy of advanced breast cancer. Moreover, FEC was better tolerated than FAC in this patient population.

Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer

2001 ◽  
Vol 28 (2D) ◽  
pp. 15-17
Author(s):  
PierFranco Conte ◽  
Barbara Salvadori ◽  
Sara Donati ◽  
Elisabetta Landucci ◽  
Alessandra Gennari
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast

New cytotoxic agents and schedules for advanced breast cancer

2001 ◽  
Vol 28 (4) ◽  
pp. 344-358 ◽  
Author(s):  
Harold J. Burstein ◽  
Craig A. Bunnell ◽  
Eric P. Winer
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Cytotoxic Agents
Sign in / Sign up

Export Citation Format

Share Document